Phosphodiesterase 4 inhibition attenuates persistent heart and lung injury by neonatal hyperoxia in rats

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 302, Issue 1, 2012, Pages

  de Visser, Yvonne P ^a   Walther, Frans J ^a,b   Laghmani, El Houari ^a   Steendijk, Paul ^a   Middeldorp, Maaike ^a   van der Laarse, Arnoud ^a   Wagenaar, Gerry T M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Bronchopulmonary dysplasia; Oxidative stress; Piclamilast; Pulmonary hypertension; Right ventricular hypertrophy

Indexed keywords

CYCLIC AMP; FIBRIN; PHOSPHODIESTERASE IV; PICLAMILAST;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; HEART INJURY; HEART RIGHT VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; HYPEROXIA; LUNG ALVEOLUS; LUNG DEVELOPMENT; LUNG INJURY; LUNG PARENCHYMA; NEWBORN PERIOD; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT;

ANIMALS; ANIMALS, NEWBORN; BENZAMIDES; BRONCHOPULMONARY DYSPLASIA; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DISEASE MODELS, ANIMAL; HEART; HEART INJURIES; HUMANS; HYPEROXIA; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; INFANT, NEWBORN; LUNG; OXIDATIVE STRESS; OXYGEN; PHOSPHODIESTERASE 4 INHIBITORS; PULMONARY ALVEOLI; PYRIDINES; RATS;

EID: 83755196228     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00041.2011     Document Type: Article

References (41)

1. Abman SH. Recent advances in the pathogenesis and treatment of persistent pulmonary hypertension of the newborn. Neonatology 91: 283-290, 2007.
2. Abman SH. Impaired vascular endothelial growth factor signaling in the pathogenesis of neonatal pulmonary vascular disease. Adv Exp Med Biol 661: 323-335, 2010.
3. Abman SH. Pulmonary hypertension in children: a historical overview. Pediatr Crit Care Med 11, Suppl 2: S4-S9, 2010.
4. Baraldi E, Filippone M. Chronic lung disease after premature birth. N Engl J Med 357: 1946-1955, 2007.
5. Boerma M, van der Wees CG, Vrieling H, Svensson JP, Wondergem J, van der LA, Mullenders LH, van Zeeland AA. Microarray analysis of gene expression profiles of cardiac myocytes and fibroblasts after mechanical stress, ionising or ultraviolet radiation. BMC Genomics 6: 6, 2005.
6. Clapp LH, Finney P, Turcato S, Tran S, Rubin LJ, Tinker A. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol 26: 194-201, 2002.
7. Conti M, Richter W, Mehats C, Livera G, Park JY, Jin C. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 278: 5493-5496, 2003.
8. Cortijo J, Iranzo A, Milara X, Mata M, Cerda-Nicolas M, Ruiz-Sauri A, Tenor H, Hatzelmann A, Morcillo EJ. Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury. Br J Pharmacol 156: 534-544, 2009.
9. De Franceschi L, Platt OS, Malpeli G, Janin A, Scarpa A, Leboeuf C, Beuzard Y, Payen E, Brugnara C. Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice. FASEB J 22: 1849-1860, 2008.
10. de Visser YP, Walther FJ, Laghmani EH, Boersma H, van der Laarse A, Wagenaar GT. Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury. Respir Res 10: 30, 2009.
11. de Visser YP, Walther FJ, Laghmani EH, van der Laarse A, Wagenaar GT. Apelin attenuates hyperoxic lung and heart injury in neonatal rats. Am J Respir Crit Care Med 182: 1239-1250, 2010.
12. de Visser YP, Walther FJ, Laghmani EH, van Wijngaarden S, Nieuwland K, Wagenaar GT. Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury. Eur Respir J 31: 633-644, 2008.
13. Donohue PK, Gilmore MM, Cristofalo E, Wilson RF, Weiner JZ, Lau BD, Robinson KA, Allen MC. Inhaled nitric oxide in preterm infants: a systematic review. Pediatrics 127: e414-e422, 2011.
14. Essayan DM. Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 108: 671-680, 2001.
15. Fan CK. Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol 533: 110-117, 2006.
16. Growcott EJ, Spink KG, Ren X, Afzal S, Banner KH, Wharton J. Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells. Respir Res 7: 9, 2006.
17. Guignabert C, Raffestin B, Benferhat R, Raoul W, Zadigue P, Rideau D, Hamon M, Adnot S, Eddahibi S. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 111: 2812-2819, 2005.
18. Hessel MH, Steendijk P, den Adel B, Schutte CI, van der Laarse A. Characterization of right ventricular function after monocrotaline-induced pulmonary hypertension in the intact rat. Am J Physiol Heart Circ Physiol 291: H2424-H2430, 2006.
19. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 351: 1425-1436, 2004.
20. Izikki M, Raffestin B, Klar J, Hatzelmann A, Marx D, Tenor H, Zadigue P, Adnot S, Eddahibi S. Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia-and monocrotaline-induced pulmonary hypertension in rats. J Pharmacol Exp Ther 330: 54-62, 2009.
21. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 163: 1723-1729, 2001.
22. Kinsella JP, Greenough A, Abman SH. Bronchopulmonary dysplasia. Lancet 367: 1421-1431, 2006.
23. Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 365: 167-175, 2005.
24. Massaro D, Teich N, Maxwell S, Massaro GD, Whitney P. Postnatal development of alveoli. Regulation and evidence for a critical period in rats. J Clin Invest 76: 1297-1305, 1985.
25. Mehats C, Bourbon J, Jarreau PH. Does PDE4 inhibition improve alveolarisation in hyperoxia-exposed immature rodents? Eur Respir J 33: 1236, 2009.
26. Mehats C, Franco-Montoya ML, Boucherat O, Lopez E, Schmitz T, Zana E, Evain-Brion D, Bourbon J, Delacourt C, Jarreau PH. Effects of phosphodiesterase 4 inhibition on alveolarization and hyperoxia toxicity in newborn rats. PLos One 3: e3445, 2008.
27. Millen J, MacLean MR, Houslay MD. Hypoxia-induced remodelling of PDE4 isoform expression and cAMP handling in human pulmonary artery smooth muscle cells. Eur J Cell Biol 85: 679-691, 2006.
28. Phillips PG, Long L, Wilkins MR, Morrell NW. cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol 288: L103-L115, 2005.
29. Rao YJ, Xi L. Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts. Acta Pharmacol Sin 30: 1-24, 2009.
30. Rybalkin SD, Bornfeldt KE. Cyclic nucleotide phosphodiesterases and human arterial smooth muscle cell proliferation. Thromb Haemost 82: 424-434, 1999.
31. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Yilmaz H, Butrous G, Ermert L, Ermert M, Weissmann N, Rose F, Guenther A, Walmrath D, Seeger W, Grimminger F. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 169: 39-45, 2004.
32. Schermuly RT, Yilmaz H, Ghofrani HA, Woyda K, Pullamsetti S, Schulz A, Gessler T, Dumitrascu R, Weissmann N, Grimminger F, Seeger W. Inhaled iloprost reverses vascular remodeling in chronic experimental pulmonary hypertension. Am J Respir Crit Care Med 172: 358-363, 2005.
33. Steinhorn RH. Neonatal pulmonary hypertension. Pediatr Crit Care Med 11, Suppl 2: S79-S84, 2010.
34. Tin W, Wiswell TE. Drug therapies in bronchopulmonary dysplasia: debunking the myths. Semin Fetal Neonatal Med 14: 383-390, 2009.
35. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 157: 351-370, 1998.
36. Tuder RM, Abman SH, Braun T, Capron F, Stevens T, Thistlethwaite PA, Haworth SG. Development and pathology of pulmonary hypertension. J Am Coll Cardiol 54: S3-S9, 2009.
37. von Poblotzki M, Rieger-Fackeldey E, Schulze A. Effects of theophylline on the pattern of spontaneous breathing in preterm infants less than 1000 g of birth weight. Early Hum Dev 72: 47-55, 2003.
38. Wagenaar GT, ter Horst SA, van Gastelen MA, Leijser LM, Mauad T, van der Velden PA, de Heer E, Hiemstra PS, Poorthuis BJ, Walther FJ. Gene expression profile and histopathology of experimental bronchopulmonary dysplasia induced by prolonged oxidative stress. Free Radic Biol Med 36: 782-801, 2004.
39. Woyda K, Koebrich S, Reiss I, Rudloff S, Pullamsetti SS, Ruhlmann A, Weissmann N, Ghofrani HA, Gunther A, Seeger W, Grimminger F, Morty RE, Schermuly RT. Inhibition of phosphodiesterase 4 enhances lung alveolarisation in neonatal mice exposed to hyperoxia. Eur Respir J 33: 861-870, 2009.
40. Yamamoto K, Dang QN, Kennedy SP, Osathanondh R, Kelly RA, Lee RT. Induction of tenascin-C in cardiac myocytes by mechanical deformation. Role of reactive oxygen species. J Biol Chem 274: 21840-21846, 1999.
41. Yi M, Jankov RP, Belcastro R, Humes D, Copland I, Shek S, Sweezey NB, Post M, Albertine KH, Auten RL, Tanswell AK. Opposing effects of 60% oxygen and neutrophil influx on alveologenesis in the neonatal rat. Am J Respir Crit Care Med 170: 1188-1196, 2004